A short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD)..

A short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD)..

A sepecific, orally bioavailable SHIP1 activator with no effect on functional androgen, oestrogen, oestrogen-related receptor α, glucocorticoid, mineralocorticoid and progesterone receptor at 30 uM.

A selective, water-soluble, in vivo long-lasting AMPA antagonist with Ki of 43 nM.

A selective, small molecule inhibitor of PIP5K1C with IC50 of 41 nM, does not ihibits other lipid kinases including PI3Ks.

A selective, reversible inhibitor of MAO-A and serotonin reuptake inhibitor as an antidepressant..

A selective, reversible inhibitor of MAO-A and serotonin reuptake inhibitor as an antidepressant..

A selective, potent peptidyl blocker of the big conductance Ca2+-activated K+ channel (BKCa, KCa1.1, MaxiK).

A selective, potent peptidyl blocker of the big conductance Ca2+-activated K+ channel (BKCa, KCa1.1, MaxiK) with IC50 of 0.25 nM.

A selective, orally bioactive and brain permeable δ-secretase (AEP.

A selective, orally active JAK3 inhibitor that reduces IL-2-mediated JAK3 tyrosine phosphorylation with cellular IC50 of 10-20 uM.

A selective, nonpeptidic, noncompetitive BACE1 inhibitor with IC50 of 3.15 uM in cell-free assays.

A selective, non-competitive inhibitor of the kinetoplastid proteasome, inhibits the chymotrypsin-like activity of the T. cruzi proteasome with IC50 of 35 nM.

A selective, G protein-biased µ-opioid receptor agonist, does not promote the development of opioid-induced mechanical allodynia (OIMA) and rapidly reverses allodynia in vivo..

A selective, G protein-biased µ-opioid receptor agonist, does not promote the development of opioid-induced mechanical allodynia (OIMA) and rapidly reverses allodynia in vivo..

A selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension..

A selective α2A receptor agonist that can reduce peripheral sympathetic outflow and thus cansues a reduction in peripheral sympathetic tone.

A selective small-molecule inhibitor of tisoprenylcysteine carboxyl methyltransferase (Icmt) with IC50 <200 nM, does not inhibit other enzymes (farensyltransferase, geranylgeranyltransferase type I, and Rce1) at concentrations up to 50 uM.

A selective small molecule toward Tec kinase-mediated tyrosine phosphorylation of FGF2 with IC50 of 7.0 uM.

A selective small molecule toward Tec kinase-mediated tyrosine phosphorylation of FGF2 with IC50 of 11.7 uM.

A selective renal outer medullary potassium channel (ROMK, Kir1.1) inhibitor with IC50 of 8 uM in T1+ flux assays, does not inhibit Kir7.1 at 100 uM.

A selective protein phosphatase PHLPP inhibitor with IC50 of 4 uM for PP2C domain of PHLPP2.

A selective monoamine oxidase B (MAO-B) inhibitor with IC50 of 1.4 uM, with less potency for MT-1 and MT-2.

A selective inhibitor of the gelatinases MMP2 and MMP9 and MMP13 with Ki of 85, 150 and 120 nM, respectively.

A selective inhibitor of 26S proteasome subunit Rpn11 with IC50 of 10±2 uM.

A selecitve small molecule toward Tec kinase-mediated tyrosine phosphorylation of FGF2 with IC50 of 8.9 uM.

A second-generation SINE, orally bioavailable Exportin 1 (XPO1,CRM1) inhibitor with markedly reduced brain penetration compared to selinexor (30-fold less).

A second generation, orally biovailable pan-genotypic HCV NS5B polymerase inhibitor with EC50 of 1-10 nM.

A ruthenium complex anticancer agent that is useful for metastatic tumors and cis-platin resistant tumors.

A rodenticide that poisons the central nervous system by uncoupling mitochondrial oxidative phosphorylation, which causes a decrease in adenosine triphosphate (ATP) synthesis..